BOM:506943 (India)
Â
Shs Dematerialised
₹
2,412.25
(0%)
Jul 23
Business Description
J.B. Chemicals & Pharmaceuticals Ltd
ISIN : INE572A01036
Share Class Description:
BOM:506943: Shs DematerialisedTotal Employee Number:
5,602Compare
Compare
Traded in other countries / regions
506943.India IPO Date
1991-01-02Description
J.B. Chemicals & Pharmaceuticals Ltd is an India-based pharmaceutical company. It is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and Active Pharmaceutical Ingredients (APIs). The company's products include various pharmaceutical dosage forms like tablets, capsules, lozenges, syrups and injectables. It has only one reportable business segment, i.e., Pharmaceuticals. The Company derives revenue from the manufacturing and marketing of pharmaceutical products. The company sells its products in India and also exports them to other international countries. The maximum revenue is generated from India.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 340.28 | |||||
Equity-to-Asset | 0.84 | |||||
Interest Coverage | 166.05 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 31.68 | |||||
Beneish M-Score | -2.56 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.7 | |||||
3-Year EBITDA Growth Rate | -7.4 | |||||
3-Year EPS without NRI Growth Rate | 20.4 | |||||
3-Year Book Growth Rate | 17.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.27 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.32 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.69 | |||||
9-Day RSI | 56.91 | |||||
14-Day RSI | 61.88 | |||||
3-1 Month Momentum % | 11.08 | |||||
6-1 Month Momentum % | 21.39 | |||||
12-1 Month Momentum % | 32.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.92 | |||||
Quick Ratio | 3.77 | |||||
Cash Ratio | 2.07 | |||||
Days Inventory | 167.91 | |||||
Days Sales Outstanding | 74.33 | |||||
Days Payable | 113.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.91 | |||||
Dividend Payout Ratio | 0.43 | |||||
3-Year Dividend Growth Rate | 33.7 | |||||
Forward Dividend Yield % | 0.77 | |||||
5-Year Yield-on-Cost % | 3.37 | |||||
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | 0.42 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.75 | |||||
Operating Margin % | 22.3 | |||||
Net Margin % | 17.11 | |||||
EBITDA Margin % | 27.49 | |||||
FCF Margin % | 14.97 | |||||
OCF Margin % | 16.97 | |||||
ROE % | 18.67 | |||||
ROA % | 15.25 | |||||
ROIC % | 20.83 | |||||
3-Year ROIIC % | 81.16 | |||||
ROC (Joel Greenblatt) % | 58.18 | |||||
ROCE % | 23.83 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 54.09 | |||||
Forward PE Ratio | 40.73 | |||||
PE Ratio without NRI | 52.58 | |||||
Shiller PE Ratio | 77.01 | |||||
Price-to-Owner-Earnings | 109.32 | |||||
PEG Ratio | 4.57 | |||||
PS Ratio | 9.26 | |||||
PB Ratio | 9.31 | |||||
Price-to-Tangible-Book | 13.48 | |||||
Price-to-Free-Cash-Flow | 62.03 | |||||
Price-to-Operating-Cash-Flow | 54.7 | |||||
EV-to-EBIT | 39.16 | |||||
EV-to-Forward-EBIT | 29.39 | |||||
EV-to-EBITDA | 32.89 | |||||
EV-to-Forward-EBITDA | 32.39 | |||||
EV-to-Revenue | 9.04 | |||||
EV-to-Forward-Revenue | 7.81 | |||||
EV-to-FCF | 60.43 | |||||
Price-to-GF-Value | 1.24 | |||||
Price-to-Projected-FCF | 5.49 | |||||
Price-to-DCF (Earnings Based) | 2.21 | |||||
Price-to-DCF (FCF Based) | 6.68 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.41 | |||||
Price-to-Graham-Number | 5.61 | |||||
| Price-to-Net-Current-Asset-Value | 18.44 | |||||
| Price-to-Net-Cash | 94.01 | |||||
Earnings Yield (Greenblatt) % | 2.55 | |||||
FCF Yield % | 1.6 | |||||
Forward Rate of Return (Yacktman) % | 12.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
J.B. Chemicals & Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 41,477.9 | ||
| EPS (TTM) (₹) | 44.6 | ||
| Beta | 0.1269 | ||
| 3-Year Sharpe Ratio | 0.84 | ||
| 3-Year Sortino Ratio | 1.47 | ||
| Volatility % | 13.78 | ||
| 14-Day RSI | 61.88 | ||
| 14-Day ATR (₹) | 40.041153 | ||
| 20-Day SMA (₹) | 2393.3425 | ||
| 12-1 Month Momentum % | 32.31 | ||
| 52-Week Range (₹) | 1603.05 - 2509.4 | ||
| Shares Outstanding (Mil) | 160.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
J.B. Chemicals & Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
J.B. Chemicals & Pharmaceuticals Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-01-19 13:30 | In 174 days | ||
| Third quarter earnings results for 2027 | 2027-01-15 | In 169 days | ||
| Second quarter earnings conference call for 2027 | 2026-11-12 14:00 | In 106 days | ||
| Second quarter earnings results for 2027 | 2026-11-11 | In 104 days | ||
| First quarter earnings conference call for 2027 | 2026-07-31 15:30 | In 2 days | ||
| First quarter earnings results for 2027 | 2026-07-30 | 2,412.25 (+0.00%) | ||
| General meeting for 2026 | 2026-06-17 15:00 | 2,192.60 (-1.56%) | ||
| INR 9.300000 Cash Dividend | 2026-05-29 | 2,202.15 (+0.61%) | ||
| Annual report for 2026 | 2026-05-25 | 2,200.00 (+0.13%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-12 08:30 | 2,207.85 (+4.35%) |
Show
Entries
J.B. Chemicals & Pharmaceuticals Ltd Frequently Asked Questions
What is J.B. Chemicals & Pharmaceuticals Ltd(BOM:506943)'s stock price today?
The current price of BOM:506943 is ₹2412.25. The 52 week high of BOM:506943 is ₹2509.40 and 52 week low is ₹1603.05.
When is next earnings date of J.B. Chemicals & Pharmaceuticals Ltd(BOM:506943)?
The next earnings date of J.B. Chemicals & Pharmaceuticals Ltd(BOM:506943) is 2026-07-30 Est..
Does J.B. Chemicals & Pharmaceuticals Ltd(BOM:506943) pay dividends? If so, how much?
The Dividend Yield %  of J.B. Chemicals & Pharmaceuticals Ltd(BOM:506943) is 0.91% (As of Today), Highest Dividend Payout Ratio of J.B. Chemicals & Pharmaceuticals Ltd(BOM:506943) was 0.48. The lowest was 0.03. And the median was 0.31. The  Forward Dividend Yield % of J.B. Chemicals & Pharmaceuticals Ltd(BOM:506943) is 0.77%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on J.B. Chemicals & Pharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers